H-CYTE (OTCMKTS:HCYTD) Stock Falls 49.5% – Time to Sell?

H-CYTE, Inc. (OTCMKTS:HCYTD) fell 49.5% during trading on Thursday. The company traded as low as $2.02 and last traded at $2.02. Approximately 400 shares were traded during trading, an increase of 288% from the average session volume of 103 shares. The stock had previously closed at $4.00.

H-CYTE Trading Down 49.5%

The company’s 50-day simple moving average is $2.02 and its 200 day simple moving average is $2.02.

H-CYTE Company Profile

H-Cyte, Inc is a clinical-stage biotechnology company focused on developing regenerative cell therapies for chronic pulmonary and respiratory diseases. Its primary investigational product, H-Cyte therapy, is designed to use a patient’s own cells in an effort to support lung repair and improve respiratory function.

The company has focused its research and development activities on conditions such as chronic obstructive pulmonary disease, emphysema and other serious lung disorders. H-Cyte’s therapies remain investigational, and their safety and effectiveness depend on the results of clinical development and regulatory review.

H-Cyte is based in the United States and has pursued clinical and commercial development of its cell-based technology for patients with significant respiratory disease.